Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
WALTHAM, Mass., Oct. 15 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced the UK Intellectual Property Office allowed application GB0907347.9 entitled N-(2-aminophenyl)-4-[N-(pyridine-3-YL)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B. The patent covers the polymorph representing a preferred stable form of entinostat (SNDX-275 formerly MS-275) with key claims covering the polymorph form B and the manufacturing process by which it is derived.
This represents the first issuance for the patent application which has been filed as a Patent Cooperation Treaty (PCT) application providing a platform for additional filings worldwide including Japan, China, India, South Africa and Brazil. The patent application also has been filed in the United States, Europe, Argentina, Venezuela, Taiwan, Kuwait and Saudi Arabia.
"We are pleased that the UK Intellectual Property Office allowed the key claims that expand the intellectual property covering entinostat with expectations for a similar outcome in the other jurisdictions in which it has been filed," said Joanna Horobin, president and chief executive officer of Syndax. "Because this important patent covers the composition of the crystalline form and the manufacturing process, it provides potential for market exclusivity in all our target indications including metastatic breast and lung cancer."
Syndax holds 36 issued patents and pending patent applications related to the composition of matter, manufacturing and use of entinostat and HDAC inhibitors in combination with other drugs.
About EntinostatEntinostat is an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor with a long half-life that allows for weekly or every-other-week dosing. Entinostat is currently being investigated in multiple phase 2 clinical studies: in advanced breast cancer in combination with aromatase